Overexpression of IL-9 receptor in diffuse large B-cell lymphoma

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 5, 2013, Pages 911-916

  Lv, Xiao ^a   Feng, Lili ^a   Fang, Xiaosheng ^a   Jiang, Yujie ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; IL 9 receptor; Prognosis

Indexed keywords

INTERLEUKIN 9 RECEPTOR; TUMOR MARKER;

AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-9; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84883033916     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Chihara T, Wada N, Ikeda J, Fujita S, Hori Y, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Morii E and Aozasa K. Frequency of intravascular large B-cell lymphoma in Japan: study of the Osaka Lymphoma Study Group. J Hematol Oncol 2011; 4: 14.
3. Smith A, Howell D, Patmore R, Jack A, and Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105: 1684-1692.
4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, and Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
5. Uyttenhove C, Simpson RJ, and Van Snick J. Functional, and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A 1988; 85: 6934-6938.
6. Simpson RJ, Moritz RL, Rubira MR, Gorman JJ, and Van Snick J. Complete amino acid sequence of a new murine T-cell growth factor P40. Eur J Biochem 1989; 183: 715-722.
7. van Leeuwen BH, Martinson ME, Webb GC, and Young IG. Molecular organization of the cyto kine gene cluster, involving the human IL-3, IL-4, IL-5,, and GM-CSF genes, on human chromosome 5. Blood 1989; 73: 1142-1148.
8. Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E, and Van Snick J. Expression cloning of the murine, and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci U S A 1992; 89: 5690-5694.
9. Mitra A, Ross JA, Rodriguez G, Nagy ZS, Wilson HL, and Kirken RA. Signal transducer, and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies. J Biol Chem 2012; 287: 16596-16608.
10. Wiener Z, Falus A, and Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histaminefree transgenic mice. Cytokine 2004; 26: 122-130.
11. Noelle RJ, and Nowak EC. Cellular sources, and immune functions of interleukin-9. Nat Rev Immunol 2010; 10: 683-687.
12. Bittner C, Merz H, Krokowski M, Briese J, Wiedemann GJ, and Feller AC. [New immunotherapeutic approaches for the treatment of anaplastic large cell lymphoma in a mouse model]. Verh Dtsch Ges Pathol 2000; 84: 187-198.
13. Renauld JC, van der Lugt N, Vink A, van Roon M, Godfraind C, Warnier G, Merz H, Feller A, Berns A, and Van Snick J. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994; 9: 1327-1332.
14. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hermelink HK, Van Snick J, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease, and large cell anaplastic lymphoma. Blood 1991; 78: 1311-1317.
15. Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, Shimizu N, Tateno M, and Harabuchi Y. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines, and patients. Clin Cancer Res 2005; 11: 8250-8257.
16. Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundstrom C, Enblad G, and Nilsson G. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 2003; 17: 2513-2516.
17. Feng LL, Gao JM, Li PP, and Wang X. IL-9 contributes to immunosuppression mediated by regulatory T cells, and mast cells in B-cell nonhodgkin's lymphoma. J Clin Immunol 2011; 31: 1084-1094.
18. Jaffe ES, Harris NL, Stein H, and Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112: 4384-4399.
19. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, and Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 2006; 108: 2407-2415.
20. Renauld JC, Vink A, Louahed J, and Van Snick J. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood 1995; 85: 1300-1305.
21. Shang Y, Kakinuma S, Amasaki Y, Nishimura M, Kobayashi Y, and Shimada Y. Aberrant activation of interleukin-9 receptor, and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6, and resistant C3H mice. In Vivo 2008; 22: 713-720.
22. Hu BS, Yu HF, Zhao G, and Zha TZ. High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma. Int J Clin Exp Pathol 2012; 5: 668-673.
23. Lv X, and Wang X. The role of interleukin-9 in lymphoma. Leuk Lymphoma 2012; Epub ahead of print.